Population PK/PD analysis of metformin using the signal transduction model

British Journal of Clinical Pharmacology

Volumn 74, Issue 5, 2012, Pages 815-823

  Chae, Jung Woo ^a   Baek, In Hwan ^b   Lee, Byung Yo ^a   Cho, Seong Kwon ^c   Kwon, Kwang Il ^a  

^a Chungnam National University   (South Korea)

^b Yuhan Research Institute   (South Korea)

^c Samnam Pharmaceuticals   (South Korea)

Author keywords

Antihyperglycaemic effect; Metformin; PK PD; Signal transduction model; Simulation

Indexed keywords

CREATININE; GLUCOSE; METFORMIN; METOPROLOL;

ADULT; ANTIDIABETIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MONTE CARLO METHOD; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADULT; BLOOD GLUCOSE; CHROMATOGRAPHY, LIQUID; CREATININE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MODELS, BIOLOGICAL; MONTE CARLO METHOD; NONLINEAR DYNAMICS; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84867344610     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04260.x     Document Type: Article

References (33)

1. McEvoy GK, Livak KG. AHFS drug information. ASPH, 2002; 3052-61.
2. Moses R, Slobodnjuk R, Boyages S, Colagiuri S, Kidson W, Carter J, Donnelly T, Moffitt P, Hopkins H. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999; 22: 119-24.
3. nd edn. Seoul, South Korea: Shinil, 2003; 433-7.
4. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541-9.
5. Lee SH, Kwon KI. Pharmacokinetic-pharmacodynamic modeling for the relationship between glucose-lowering effect and plasma concentration of metformin in volunteers. Arch Pharm Res 2004; 27: 806-10.
6. Groenendaal D, Freijer J, Roiser A, de Mik D, Nicholls G, Hersey A, Ayton AD, Danhof M, de Lange EC. Pharmacokinetic/pharmacodynamic modeling of the EEG effects of opioids: the role of complex biophase distribution kinetics. Eur J Pharm Sci 2008; 34: 149-63.
7. Foti D, Chiefari E, Iuliano R, Brunetti L, Paonessa F, Manfioletti G, Barbetti F, Brunetti A, Croce CM, Fusco A. Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice. Nat Med 2005; 11: 765-73.
8. Landersdorfer CB, Jusko WJ. Pharmacokinetic/pharmacodynamic modeling in diabetes mellitus. Clin Pharmacokinet 2009; 47: 417-48.
9. Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49: 721-49.
10. Sambol NC, Chiang J, O'Conner M, Liu CY, Lin ET, Goodman AM, Benet LZ, Karam JH. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol 1996; 36: 1012-21.
11. Hong Y, Rohatagi S, Habtemariam B, Walker JR, Schwartz SL, Mager DE. Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus. J Clin Pharmacol 2008; 48: 696-707.
12. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65: 385-411.
13. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-9.
14. Wang Y, Tang Y, Gu J, Fawcett JP, Bai X. Rapid and sensitive liquid chromatography-tandem mass spectrometric method for the quantification in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 808: 215-9.
15. Beal SL, Sheiner LB, Boekmann AJ, eds. NONMEM User Guides. Ellicott City, MD: Icon Development Solutions, 2006.
16. Lindblom L, Pihlgren P, Jonsson EN. PsN toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79: 241-57.
17. Jonsson N, Karlsson MO. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64.
18. Sun YN, Jusko WJ. Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J Pharm Sci 1998; 87: 732-7.
19. Mager DE, Jusko WJ. Pharmcodynamic modeling of time dependent transduction systems. Clin Pharmacol Ther 2001; 70: 210-6.
20. Perlstein I, Stepensky D, Krzyzanski W, Hoffman A. A signal transduction pharmacodynamic model of the kinetic of the parasympathomimetic activity of low dose scopolamine and atropine in rats. J Pharm Sci 2002; 91: 2500-10.
21. Iwi G, Millard RK, Palmer AM, Preece AW, Saunders M. Bootstrap resampling: a powerful method of assessing confidence intervals for doses form experimental data. Phys Med Biol 1999; 44: 55-62.
22. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001; 28: 171-92.
23. Ette EI, Williams PJ, Kim YH, Lane JR, Liu MJ, Capparelli EV. Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol 2003; 43: 610-23.
24. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed effects population models. Comput Methods Programs Biomed 1999; 59: 19-29.
25. Post TM, Freijer JI, Ploeger BA, Danhof M. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 2008; 35: 185-202.
26. Xu Z, Vu T, Lee H, Hu C, Ling J, Yan H, Baker D, Beutler A, Pendley C, Wagner C, Davis HM, Zhou H. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol 2009; 49: 1056-70.
27. Xu Z, Seitz K, Fasanmade A, Ford J, Williamson P, Xu W, Davis HM, Zhou H. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol 2008; 48: 681-95.
28. Royer B, Yin W, Pegram M, Ibrahim N, Villanueva C, Mir D, Erlandsson F, Pivot X. Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer. Br J Cancer 2010; 102: 827-32.
29. Vitaly R, Igor NT. Rx drug information. 2007. Available at http://www.druglib.com/druginfo/metformin/description_pharmacology/ (last accessed 12 April 2012).
30. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996; 30: 359-71.
31. Watanalumlerd P, Christensen JM, Ayres JW. Pharmacokinetic modeling and Simulation of gastrointestinal transit effects on plasma concentrations of drugs from mixed immediate-release and enteric-coated pellet formulations. Pharm Dev Technol 2007; 12: 193-202.
32. Williams-Herman D, Johnson J, Teng R, Golm G, Kaufman KD, Goldstein BJ, Amatruda JM. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 442-51.
33. Aschner P, Katzeff HL, Guo H, Williams-Herman D, Kaufman KD, Goldstein BJ. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 252-61.